ECL vs HWKN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ECL and HWKN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ECL and HWKN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Ecolab is the global leader in water treatment, hygiene, and infection-prevention solutions, serving customers across foodservice, hospitality, healthcare, food and beverage processing, manufacturing, and increasingly high-tech and data-center cooling. The business is built on a razor-and-blade model: Ecolab places dispensing equipment and sensors on-site, then sells the recurring chemicals, service, and software that keep those systems running. Following a 2025 segment reorganization, the company reports through Global Water (formerly Global Industrial), Global Institutional and Specialty, Global Life Sciences, and Global Pest Elimination, with faster-growing units like Life Sciences, Pest Elimination, Global High-Tech, and Ecolab Digital called out as growth engines.

Full ECL guide

Hawkins, Inc. (NASDAQ: HWKN) is a specialty chemicals company founded in 1938 and headquartered in Roseville, Minnesota. It operates through three segments: Water Treatment (chemicals, equipment, and services for potable water, municipal and industrial wastewater, pools, and agriculture), Industrial (chemicals and blends for food, pharmaceutical, energy, electronics, and plating customers), and Health and Nutrition (ingredient distribution and formulation for supplements, functional foods, and personal care). Water Treatment has become the growth engine, expanded aggressively through a string of regional acquisitions such as WaterSurplus, and in September 2026 Hawkins added Dave Symonds & Associates in Florida and Eagle Labs in the Dallas-Fort Worth region of Texas.

Full HWKN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ECL drivers: Recurring razor-and-blade model; Water scarcity and hygiene secular demand.
• HWKN drivers: Water Treatment roll-up; Profitability and margin mix.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most cited risk is valuation: ECL trades at ~39x trailing and ~31x forward earnings as of October 2026, so slower growth or a guidance miss can pressure the stock even when the underlying business is healthy. For HWKN, the largest risk is valuation: the stock trades at about 34x trailing and 28x forward earnings, well above the chemicals-industry and peer averages, so any growth disappointment can compress the multiple, as the 21% one-year decline after a string of earnings misses has shown.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ECL if you believe its drivers more; HWKN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ECL and HWKN guides.

ECL. Ecolab carries a premium valuation, with a trailing P/E near 39 and a forward P/E around 31, a sign of investor confidence in its recurring model and steady growth. Consensus looks for 2026 EPS of ~$8.16 and ~$9.40 in 2027, and the October 27 report (consensus ~$2.17 EPS on ~$4.7 billion revenue) will test that path. Figures are approximate and move with each quarterly report and share-price changes.

HWKN. The multiple has come down: at about $133, Hawkins trades near 34x trailing earnings and 18x EV/EBITDA, compared with a mid-to-high 30s P/E and roughly 20x EV/EBITDA in mid-2026, still a premium to the US chemicals sector and close peers. Analysts expect only about 4% EPS growth in fiscal 2027 (to about $4.11) before roughly 14% in fiscal 2028. Fiscal Q2 2027 results are due October 26, with consensus EPS of about $1.18 on revenue near $303 million.

Headline figures (approximate, October 2026): ECL shows revenue (ttm) ~$16.8B, up ~9.7% in the latest quarter, margins (gross / operating / net) ~44% / ~18.5% / ~12.6%, net income (ttm) ~$2.1B, q2 2026 adjusted eps ~$2.09 vs ~$2.08 consensus; HWKN shows revenue (ttm) ~$1.11 billion, revenue growth (q1 fy2027, yoy) ~7.6%, net income (ttm) ~$81 million, operating / net margin (ttm) ~12% / ~7%.

ECL and HWKN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ECL and HWKN exposure against your real portfolio. It is not an investment adviser.